Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lisdexamfetamine dimesylate

Shire Basingstoke

Shire wins EU approval for prolonged-release ADHD drug

First treatment in its class to be licensed for ADHD in Europe

- PMLiVE

Shire adds Sara Mathew to board of directors

Comes as firm aims to become global biotechnology leader

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

Shire Basingstoke

Shire buys into eyecare specialist

Will complement its investigational dry eye drug lifitegrast

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

Shire Basingstoke

Shire enters research partnership for rare eye disease

Will work with Foundation Fighting Blindness on treatment for adRP

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

Shire Basingstoke

Silver lining as Shire rare disease programme hits a setback

Alagille syndrome candidate fails to meet phase II targets

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links